Patent · US Active

Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

US10570190B2 · kind B2 · utility

0Cited by

2References

1Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Kathrin Tissot · Schwanau, DE
Stefan Ewert · Basel, CH
Adrian Auf Der Maur · Bellinzona, CH
Alcide Barberis · Bioggio, CH
Dominik Escher · Kreuzlingen, CH

Key dates

Filing date	Oct 30, 2018
Grant date	Feb 25, 2020
Priority date	—
Expiry date	Oct 30, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.